MDWD News and Press, MediWound Ltd. From 04/25/24

Oral presentations include additional comparative data between EscharEx ® and SANTYL ® , and new analyses show strong correlation between wound bed preparation and wound healing Analyses validate the planned design and endpoints of the upcoming Phase II...

Shares of MediWound Ltd. (NASDAQ: MDWD) traded at a new 52-week high today and are currently trading at $17.39. So far today, approximately 35,312 shares have been exchanged, as compared to an average 30-day volume of 101.83k shares. MediWound Ltd., a biopharmaceutical company, develops, manu...

A look at the top 10 most actives in the United States Jaguar Health Inc. (JAGX) rose 50.1% to $0.1783 on volume of 599,794,977 shares WiSA Technologies Inc. (WISA) rose 248.6% to $6.1 on volume of 197,912,579 shares PROSHARES TRUST (SQQQ) rose 0.0% to $11.44 on volume of 182,001,060 shar...

2024-03-21 11:54:03 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips MediWound (NASDAQ: MDWD ) just reported results for the fourth quarter of 2023. MediWound reported earnings per share of -19 cents. This was above the analyst estimate for...

2024-03-21 11:35:23 ET MediWound Ltd. (MDWD) Q4 2023 Earnings Conference Call March 21, 2024, 08:30 AM ET Company Participants Gaia Shamis - LifeSci Advisors Ofer Gonen - Chief Executive Officer Barry Wolfenson - Executive Vice President of Strategy & Corpora...

2024-03-21 07:19:09 ET More on MediWound MediWound stock climbs 9% on Phase 2 data for wound care treatment FDA accepts MediWound application for NexoBrid pediatric approval Seeking Alpha’s Quant Rating on MediWound Historical earnings data for MediWou...

X4 Pharmaceuticals Inc. (XFOR) is expected to report $-0.15 for Q4 2023 Li Ning Co., Ltd. ADR (LNNGY) is expected to report for Q4 2023 Xos Inc. (XOS) is expected to report $-2.4 for Q4 2023 PainReform Ltd. (PRFX) is expected to report for quarter end 2023-12-31 Muenchener Rueckve...

$19 million revenue in 2023; $24 million projected revenue in 2024 NexoBrid ® commercially launched in U.S., Japan, India Potential blockbuster EscharEx ® to begin Phase III in the second half of 2024 $42 million cash runway through profitabilit...

2024-03-20 11:29:28 ET More on MediWound MediWound stock climbs 9% on Phase 2 data for wound care treatment FDA accepts MediWound application for NexoBrid pediatric approval Seeking Alpha’s Quant Rating on MediWound Historical earnings data for MediWou...

YAVNE, Israel, March 14, 2024 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), the global leader in next-generation enzymatic therapeutics for tissue repair, today announced that the Company will release its financial results for the fourth quarter and full year ended December 31, 2023 on Thurs...